Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours

Human Genomics

Volumn 9, Issue 1, 2015, Pages

  Thomas, Laura E ^a   Winston, Jincy ^a   Rad, Ellie ^a   Mort, Matthew ^a   Dodd, Kayleigh M ^a   Tee, Andrew R ^a   McDyer, Fionnuala ^b   Moore, Stephen ^b   Cooper, David N ^a   Upadhyaya, Meena ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Almac Sciences   (United Kingdom)

Author keywords

Copy number alterations; Gene expression profiling; MPNSTs; NF1; SPP1

Indexed keywords

ADH1B PROTEIN; CCT5 PROTEIN; CD72 ANTIGEN; COL10A1 PROTEIN; CSRP1 PROTEIN; EFHC2 PROTEIN; FAM177A1 PROTEIN; FAP PROTEIN; FLJ42200 PROTEIN; GLUTATHIONE; GRIK2 PROTEIN; GRIK3 PROTEIN; GTDC1 PROTEIN; KIAA0746 PROTEIN; KRTAP13N4 PROTEIN; NSBP1 PROTEIN; OSTEOPONTIN; PEG3 PROTEIN; PROTEIN; PTGIS PROTEIN; SHORT HAIRPIN RNA; SLC25A12 PROTEIN; TDP1 PROTEIN; UNCLASSIFIED DRUG; SPP1 PROTEIN, HUMAN;

ARTICLE; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MUTATION; NEUROFIBROMATOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; WNT SIGNALING PATHWAY; WOUND HEALING; BIOSYNTHESIS; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS TYPE 1; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; OSTEOPONTIN;

EID: 84927752713     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/s40246-015-0025-3     Document Type: Article

References (70)

1. Huson S. The neurofibromatoses: classification, clinical features and genetic counselling. In: Kaufmann D, editor. Neurofibromatoses (monographs in human genetics), vol. 16. Switzerland: S Karger AG; 2008. p. 1-20.
2. Upadhyaya M. Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Front Biosci. 2011;16:937-51.
3. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumours in neurofibromatosis 1. Cancer Res. 2002;1(62(5)):1573-7.
4. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;9:311-4.
5. Katz D, Lazar A, Lev D. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med. 2009;11:e30.
6. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman J. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005;65:205-11.
7. Mautner VF, Kluwe L, Friedrich RE, et al. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions. J Med Genet. 2010;47:623-30.
8. Ferner RE, Hughes RA, Hall SM, Upadhyaya M, Johnson MR. Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet. 2004;41:837-41.
9. Evans DG, Huson SM, Birch JM. Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res. 2012;2:17.
10. Beert E, Brems H, Daniëls B, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chrom Cancer. 2011;50:1021-32.
11. Lothe RA, Karhu R, Mandahl N, et al. Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res. 1996;56:4778-81.
12. Bridge Jr RS, Bridge JA, Neff JR, Naumann S, Althof P, Bruch LA. Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. J Clin Pathol. 2004;57:1172-8.
13. Watson MA, Perry A, Tihan T, et al. Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol. 2004;14:297-303.
14. Storlazzi CT, Brekke HR, Mandahl N, et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol. 2006;209:492-500.
15. Shen MH, Mantripragada K, Dumanski JP, Frayling I, Upadhyaya M. Detection of copy number changes at the NF1 locus with improved high-resolution array CGH. Clin Genet. 2007;72:238-44.
16. Kresse SH, Skårn M, Ohnstad HO, et al. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. Mol Cancer. 2008;7:48.
17. Mantripragada KK, Spurlock G, Kluwe L, et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res. 2008;14:1015-24.
18. Mantripragada KK, Díaz de Ståhl T, Patridge C, et al. Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32 K BAC array. Genes Chrom Cancer. 2009;48:897-907.
19. Brekke HR, Kolberg M, Skotheim RI, et al. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. NeuroOncol. 2009;11:514-28.
20. Miller SJ, Jessen WJ, Mehta T, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med. 2009;1:236-48.
21. Pemov A, Park C, Reilly KM, Stewart DR. Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency. BMC Genomics. 2010;11:194.
22. Brekke HR, Ribeiro FR, Kolberg M, et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol. 2010;28:1573-82.
23. Subramanian S, Thayanithy V, West RB, et al. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol. 2010;220:58-70.
24. Chai G, Liu N, Ma J, et al. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Sci. 2010;101:1997-2004.
25. Upadhyaya M, Spurlock G, Thomas L, et al. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Hum Mutat. 2012;33:763-76.
26. Mo W, Chen J, Patel A, et al. CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 2013;152:1077-90.
27. Rahrmann EP, Watson AL, Keng VW, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet. 2013;45:756-66.
28. Watson AL, Rahrmann EP, Moriarity BS, et al. Canonical Wnt/β-catenin signaling drives human Schwann cell transformation, progression, and tumor maintenance. Cancer Discov. 2013;6:674-89.
29. Largaespada D, Ratner N. Interweaving the strands: β-catenin, an HIV co-receptor, and Schwann cell tumors. Cancer Cell. 2013;23:269-71.
30. Luscan A, Shackleford G, Masliah-Planchon J, et al. The activation of the WNTWnt signalling pathway is a hallmark in Neurofibromatosis type 1 tumorigenesis. Clin Cancer Res. 2013;15(20(2)):358-71.
31. Huang N, Shah PK, Li C. Lessons from a decade of integrating cancer copy number alterations with gene expression profiles. Brief Bioinformatics. 2012;13:305-16.
32. Hassan A, Mokhtar NM, Sin K, Mohammed Rose I, Sagap I, Harun R, et al. Integrated analysis of copy number variation and genome-wide expression profiling in colorectal cancer tissues. PLoS ONE. 2014;2(9(4)):e92553.
33. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Brit J Cancer. 2004;90:1877-81.
34. Pradervand S, Paillusson A, Thomas J, et al. Affymetrix Whole-Transcript Human Gene1.0 ST array is highly concordant with standard 3′ expression arrays. Biotechniques. 2008;44:759-62.
35. Xi L, Feber A, Gupta V, et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res. 2008;36:6535-47.
36. Thorsen K, Sørensen KD, Brems-Eskildsen AS, et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics. 2008;7:1214-24.
37. Kapur K, Xing Y, Ouyang Z, Wong WH. Exon arrays provide accurate assessments of gene expression. Genome Biol. 2007;8:R82.
38. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Current Mol Med. 2001;1:621-32.
39. Bramwell VHC, Tuck AB, Wilson SM, et al. Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol Ther. 2005;4:1336-41.
40. Hoshi N, Sugino T, Suzuki T. Regular expression of osteopontin in granular cell tumor: distinctive feature among Schwannian cell tumors. Pathol Int. 2005;55:484-90.
41. Rangaswami H, Bulbule A, Kundu G. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16:79-87.
42. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008;27:103-18.
43. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001;1552:61-85.
44. Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010;10:71-81.
45. Ahmed M, Behera R, Chakraborty G, et al. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets. 2011;15:1113-26.
46. Luo X, Ruhland MK, Pazolli E, Lind AC, Stewart SA. Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway. Mol Cancer Res. 2011;9:1018-29.
47. Rao G, Du L, Chen Q. Osteopontin, a possible modulator of cancer stem cells and their malignant niche. Oncoimmunology. 2013;2:e24169.
48. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006;17:463-74.
49. Tilli TM, Mello KD, Ferreira LB, et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate. 2012;72:1688-99.
50. Guo X, Zhang YP, Mitchell DA, Denhardt DT, Chambers AF. Identification of a Ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol. 1995;15:476-87.
51. Mason CK, McFarlane S, Johnston PG, et al. Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Cancer Ther. 2008;7(3):548-58.
52. The cancer genome atlas [http://cancergenome.nih.gov]
53. Gu W, Choi H, Ghosh D. Global associations between copy number and transcript mRNA microarray data: an empirical study. Cancer Inform. 2008;6:17-23.
54. Thomas L, Mautner VF, Cooper DN, Upadhyaya M. Molecular heterogeneity in malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1. Hum Genomics. 2012;4(6):18.
55. Spivey TL, De Giorgi V, Zhao Y, et al. The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics. 2012;13:156.
56. Lu TP, Lai LC, Tsai MH, et al. Integrated analyses of copy number variations and gene expression in lung adenocarcinoma. PLoS ONE. 2011;6:e24829.
57. Conan copy number analysis [http://www.sanger.ac.uk/research/projects/cancergenome/copy-number.html]
58. COSMIC catalogue of somatic mutations in cancer [http://cancer.sanger.ac.uk/cancergenome/projects/cosmic]
59. Kleinjan DA, Lettice LA. Long-range gene control and genetic disease. Adv Genet. 2008;1:339-88.
60. Henrichsen CN, Chaignat E, Reymond A. Copy number variants, diseases and gene expression. Hum Mol Genet. 2009;18(R1):R1-8.
61. Hyman E, Kauraniemi P, Hautaniemi S, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 2002;62:6240-5.
62. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142:219-32.
63. Reilly KM. Extending the convergence of canonical Wnt signaling and classic cancer pathways for treatment of malignant peripheral nerve sheath tumors. Cancer Discov. 2013;6:610-2.
64. Vinas JL, Sola A, Jung M, Mastora C, Vinuesa E, Pi F, et al. Inhibitory action of Wnt target gene osteopontin on mitochondrial cytochrome c release determines renal ischemic resistance. Am J Physiol Renal Physiol. 2010;299:F234-42.
65. Blair SL, Heerdt P, Sachar S, et al. Glutathione metabolism in patients with non-small cell lung cancers. Cancer Res. 1997;57:152-5.
66. Sun Z, Chen J, Aakre J, et al. Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients predicts survival of small-cell lung cancer patients. Ann Oncol. 2011;21:2011-6.
67. Harder A, Titze S, Herbst L, Harder T, Guse K, Tinschert S, et al. Monozygotic twins with neurofibromatosis type 1 (NF1) display differences in methylation of NF1 gene promoter elements, 5′ untranslated region, exon and intron 1. Twin Res Hum Genet. 2010;13(6):582-94.
68. Titze S, Peters H, Währisch S, Harder T, Guse K, Buske A, et al. Differential MSH2 promoter methylation in blood cells of neurofibromatosis type 1 (NF1) patients. Eur J Hum Genet. 2010;18(1):81-7.
69. Rohde F, Rimcus C, Friederichs J, et al. Expression of osteopontin, a target gene of de-regulated Wnt signalling predicts survival of colon cancer. Int J Cancer. 2007;121:1717-23.
70. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-64.